Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Current Assets to Total Assets Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: -14.46%

Freeline Therapeutics Holdings Plc Current Assets to Total Assets Ratio 2 year CAGR is -14.46% for the Trailing 12 Months (TTM) ending September 30, 2023, a -20.80% change year over year. The current assets to total assets ratio measures the proportion of a company's current assets in relation to its total assets. It is calculated by dividing current assets by total assets. This ratio indicates the percentage of a company's total assets that are in the form of current assets, such as cash, receivables, and inventory. It provides insights into the company's liquidity and the extent to which its assets are readily convertible to cash in the short term. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Freeline Therapeutics Holdings Plc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.72, a -24.10% change year over year.
  • Freeline Therapeutics Holdings Plc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.94, a 2.09% change year over year.
  • Freeline Therapeutics Holdings Plc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.92.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email